The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS: This study consisted of 11 541 men with coronary heart disease screened to participate in a secondary cardiac prevention trial. MS was defined according to modified NCEP/ATP III criteria. Multivariable regression analysis accounting for competing risks was performed using a modified Cox proportional hazard model in order to assess the association between diabetes, the MS and the subsequent development of prostate cancer. RESULTS: At baseline, subjects were classified into one of the four groups: (1) 6119 (53%) with neither diabetic mellitus nor MS, (2) 3376 (29%) with the MS but without diabetes, (3) 560 (5%) with diabetes mellitus but without MS and (4) 1486 (13%) with both conditions. Median follow-up was 12.7 years (range 0-15.7 years). During follow-up, 459 new cases of prostate cancer were recorded. The age-adjusted hazard ratio (HR) for prostate cancer was reduced in diabetic patients compared with those without diabetes, 0.54 and 95% confidence interval of 0.40-0.73. No significant association was noted between the presence of MS and prostate cancer development. On multivariate analysis, diabetes mellitus continued to protect against the development of prostate cancer, this was more pronounced in the absence of MS (HR ¼ 0.43, P ¼ 0.01 for diabetes in the absence of MS; HR ¼ 0.64, P ¼ 0.08 in the presence of MS). CONCLUSIONS: The results of this study indicate an inverse association between type 2 diabetes mellitus and prostate cancer risk.
INTRODUCTION
Prostate cancer is the most common cancer in men in the western world, affecting more than 200 000 men a year in the United States alone. 1 While older age, family history and race are wellestablished risk factors for prostate cancer, accumulating data suggest a role for diet, lifestyle and anthropometric features as independent risk factors. 2, 3 Metabolic syndrome (MS), also called insulin resistance syndrome, is defined as a constellation of metabolic abnormalities, including glucose intolerance, dyslipidemia, hypertension and central obesity. 4 The syndrome has been associated with an increased incidence of colorectal 2 endometrial 5 and breast cancer. 6 However, the role of the MS as a risk factor for prostate cancer is controversial.
Diabetes mellitus type 2 is associated with an increased risk of development of various neoplasms, including colon, pancreatic, breast, endometrial, liver and bladder cancer. 7, 8 Conversely, diabetes mellitus type 2 has been associated with reduced prostate cancer risk, and meta-analyses suggest an B15% risk reduction among diabetic patients. [9] [10] [11] [12] However, owing to the historical nature (with long follow-up) of these studies most were not able to adjust for shared risk factors we now know to be relevant. Of the 19 studies included in the meta-analysis of Kasper and Giovannucci, 9 only five adjusted for body mass index (BMI) and only one adjusted for cholesterol levels.
Patients with the MS and/or diabetes are at increased risk of death owing to other causes. Few published studies satisfactorily accounted for these competing risks, potentially underestimating the cancer risk associated with these conditions. Thus, the strength of the association between these chronic conditions and prostate cancer risk remains uncertain.
We report here on the association between type 2 diabetes mellitus, the MS and the development of prostate cancer among 11 541 men with coronary heart disease who were screened for inclusion into a prospective clinical trial (the Bezafibrate Infarction Prevention (BIP) study).
MATERIALS AND METHODS
The BIP study events and mortality. 13 Data collection, design and rationale of the trial have been published. 14 Between February 1990 and October 1992, 12 529 men and 2995 woman aged 36 to 74 years with known coronary heart disease were screened for the trial in 18 Israeli medical centers. Patients with insulin-dependent diabetes mellitus were excluded from screening. Those who were screened but not recruited either did not meet one or more of the inclusion criteria or did not consent to take part in the randomized study.
During the first screening visit, clinical, demographic and metabolic characteristics of patients were recorded and a complete physical examination preformed. At baseline, medical histories were obtained, and plasma glucose and lipids were assessed at a central study laboratory. A dietary consultation was given to all patients whose initial blood lipid profile did not exclude them from consideration for recruitment and randomization to the subsequent BIP trial (serum total cholesterol between 180 and 250 mg dl À 1 , low-density lipoprotein cholesterol p180 mg dl À 1 (p160 mg dl À 1 for patients o50 years), high-density lipoprotein cholesterol (HDL-C) p45 mg dl À 1 and triglycerides p300 mg dl
) and who attended a second screening visit.
Diabetes mellitus was defined as fasting plasma glucose levels X126 mg dl À 1 (7.0 mmol l À 1 ). MS was defined based on modified NCEP/ ATP III criteria. 15 Patients were considered as having the syndrome if they had X3 of the following components: (1) hypertension defined as systolic blood pressure X130 mm Hg and/or diastolic blood pressure X85 mm Hg or by history of hypertension, (2) raised plasma triglycerides (X150 mg dl À 1 (1.7 mmol l À 1 )), (3) low HDL cholesterol levels (o40 mg dl À 1 in men), (4) impaired fasting glucose defined as fasting plasma glucose concentration X110 mg dl À 1 (6.1 mmol l
), but less than the criteria for diabetes of 4125 mg dl À 1 (X7.0 mmol l
) and (5) a BMI X30 kg m À 2 was used to define obesity. After an initial 2 months of a lipid-lowering diet, 3122 eligible patients were included in the BIP trial and received either bezafibrate or placebo for a mean of 6.2 years.
Study cohort and assessment of prostate cancer Of the 12 529 male patients screened, 988 (7.9%) were excluded from analysis (owing to loss of follow-up; prior malignancies; or lack of demographic information). The final study sample, therefore, comprised 11 541 men with complete data on cancer status and MS. Participants were divided into four groups according to baseline parameters: (1) 
Laboratory methods
Blood samples, which were collected in the 18 participating medical centers using standardized equipment and procedures, were transferred in cooled containers to the Central Laboratory at the Institute of Physiological Hygiene Laboratory at the E. Wolfson Medical Center, Holon. Blood samples were drawn after 12 h of fasting to determine serum levels of cholesterol, HDL-C and triglycerides. Laboratory measurements were performed using standard automated procedures with commercially available kits (Roche Diagnostics, Indianapolis, IN, USA). HDL-C was measured by precipitation. Accuracy and precision of lipid and lipoprotein determinations were under periodic surveillance by the Centers for Disease Control/National Heart, Lung, and Blood Institute's Lipids Standardization Program; other determinations, including the safety variables, were under surveillance by the WellcomeMurex Diagnostic Clinical Chemistry Quality Assessment Program.
Statistical analysis
Statistical analysis was performed with SAS software (9.2; SAS Institute, Cary, NC, USA). 'Person-years at risk' were calculated from the time of baseline clinical screening to date of prostate cancer diagnosis, or other cancer diagnosis, death or end of follow-up on 31 December 2005. 'Age adjusted prostate cancer rates' were computed by means of an SAS macro using the total sample as a standard.
We defined four groups of interest (neither diabetes nor MS, MS without diabetes, diabetes without MS, and both MS and diabetes) and compared the main covariates between the groups using the w 2 test for categorical variables, analysis of variance for continuous variables and the KruskalWallis non-parametric one-way test for the length of follow-up. In the latter case, we used only patients without cancer or death. In addition to the overall test, we compared all groups with the 'neither diabetes nor MS' group using the Wilcoxon test for the follow-up period, and analysis of variance for other continuous outcomes.
To account for the competing risks of other cancer or death, prostate cancer diagnosis probabilities during follow-up were estimated We analyzed the effect of various covariates on the prostate cancer and other cancer by simple (Table 2 ) and multiple ( Table 3) cumulative incidence regression using Fine-Gray model. 18 According to design, only the first cancer diagnosed was recorded, making different types of cancer mutually exclusive. Therefore for these two outcomes (prostate and nonprostate cancer), the competing events were other type of cancers and death. The calculations were done using SAS macro 'pshreg' of Kohl and Heinze. 19 For death, different types of cancer are not a competing risk because they can occur before death and the date of death was recorded. However, occurrence of any cancer may affect the hazard of death. Therefore, we performed multiple Cox proportional hazard regression with prostate and non-prostate cancer as time-varying variables, this was done using SAS procedure 'phreg'.
RESULTS
The study population comprised 11 541 men with coronary heart disease, none of whom had diabetes mellitus type 1. The characteristics of the study population at screening for the BIP trial are presented in Table 1 . At baseline, 6119 (53%) with neither diabetic mellitus type 2 nor MS, 3376 (29%) had the MS but without diabetes type 2, 560 (5%) had diabetes mellitus type 2 but without MS and 1486 (13%) had both conditions. Median age of subjects was 59 years ( Table 1) . As expected, patients with MS had more obesity, higher mean total cholesterol, lower HDL cholesterol, higher mean triglycerides and higher mean systolic and diastolic blood pressure compared with both other groups ( Table 1) . Median follow-up ranged from 9.1 to 12.2 years for the four groups (Table 1) .
During 119 894 person-years of follow-up, 459 new cases of prostate cancer were recorded. The associations between diabetes, the MS, specific components of the syndrome and prostate cancer development are presented in Table 2 and Figure 1 . A significantly reduced age-adjusted hazard ratio (HR) was observed in diabetic patients compared with men without diabetes, 0.54 (95% confidence interval of 0.40-0.73). The protective effect of diabetes started after 5 years of follow-up (Figure 1) . A weaker association between the MS (in the absence of diabetes) and decreased prostate cancer risk was observed (age-adjusted HR 0.78, 95% confidence interval 0.63-0.96), similar associations were noted for obesity and triglyceride levels. No association was observed between intermediate blood glucose levels, HDL cholesterol levels, hypertension and prostate cancer risk. Table 3 presents a multivariate analysis of the association of study variables with prostate cancer risk considering other cancers and death as competing events. The only significant associations were with age and the presence of diabetes in the absence of MS, there was a borderline association for diabetes in the presence of MS.
DISCUSSION
We have demonstrated that a baseline diagnosis of diabetes mellitus type 2, but not the MS, is associated with a lower likelihood of the subsequent development of prostate cancer within a cohort of patients with ischemic heart disease. 
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We estimate the prostate cancer risk reduction among diabetic patients to be somewhat larger effect than the 15-20% reported by others. 10, 11, 20 This may be explained by the characteristics of our cohort and analyses. Our cohort consisted of men screened at a relatively older age (mean 59 years) compared with previous studies and followed up for a relatively long time (median 12.7 years). As the protective effect of diabetes was noted only after more than 5 years of follow-up (Figure 1) , and prostate cancer is predominantly a disease of the elderly, it is possible that studying a younger cohort for shorter period of time will not allow full recognition of the protective effect of diabetes. Our data regarding diabetes and the MS were collected prospectively and systematically by physicians, based upon appropriate blood tests. The fact that we used a national registry for both cancer diagnosis and mortality data decreased the number of subjects lost to follow-up. Importantly, in our study competing risks were accounted for. When applied to the development of secondary cancers the Kaplan-Meyer technique censors deceased individuals; however, such an analysis is based upon the incorrect assumption that deceased individuals may develop prostate cancer in the future. The 'cumulative incidence function' technique applied here is more appropriate. 21 A number of studies and meta-analysis have examined the relationship between diabetes mellitus and prostate cancer development. Five meta-analyses 9,11,22-24 found strong evidence that type 2 diabetes is significantly inversely associated with risk of developing prostate cancer (relative risk 0.7-0.9, in keeping with our manuscript's conclusions). One meta-analysis confined to studies performed in Asia found a positive association 25 Such studies are complex owing to the close association between diabetes and other metabolic abnormalities, the use of anti-diabetic medications that may affect cancer development 26 and the increased mortality associated with a diagnosis of diabetes.
A potential confounding factor may be reduced rates of prostate cancer screening among diabetic patients. While diabetes has been linked to reduced utilization of cancer screening among women in the United States, 27 utilization of prostate cancer screening among diabetic men has not been examined to date. As all patients in our cohort had coronary heart disease and were not healthy individuals, it is less likely that the presence of diabetes specifically excluded them from screening owing to comorbidity concerns. Furthermore, all study participants had complete healthcare coverage and received similar primary and secondary health-care services provided by the national health-care plan. It is, therefore, less likely that our results merely reflect reduced prostate cancer screening among diabetic men.
We found no association between the presence of the MS itself (defined as at least 3-component components) and the risk of developing prostate cancer. Previous studies (summarized in Table 4 ) have come to inconsistent conclusions regarding the interaction between the MS and prostate cancer risk, possibly reflecting the different populations studied, definitions of MS used and methodologies applied.
There are several limitations to our study. The INCR collects all cancer cases, without information regarding stage or pathological characteristics. We do not know whether the prostate cancers among diabetic subjects were of a similar stage or grade to that seen in non-diabetic subjects. Further, this is a long-term study that covers 14 years; we only have data regarding baseline diabetes and the MS, but lack information about the subsequent development of these conditions. The incidence of both MS and diabetes mellitus increase with age (with the big increase occurring between the ages of 40-55 years of age for MS, 28 and 45-65 years of age for diabetes mellitus type 2 29 ). As the median age of our cohort was 59 years, it is likely that a certain percentage of subjects classified as not having these conditions developed one of these diseases during follow-up. A possible effect of this bias is to decrease the size of the observed (protective) effect. All subjects in this study had coronary heart disease, limiting the generalizability of our results to the wider population.
MS is associated with 'central obesity', as opposed to subcutaneous and intramuscular fat deposition, therefore in the majority of contemporary definitions of MS waist circumference is a criteria. 30 An important weakness of the study is that 'waist circumference' was not recorded in the early 1990s when the baseline data were collected, we therefore were forced to use BMI as a surrogate for central obesity. There is a strong, yet imperfect, correlation between BMI and 'waist circumference' (correlation coefficient of 0.8). 31 Further, we lack data regarding a number of variables that would ideally have been included as covariants in the multivariate analysis, including family history, use of medications including aspirin and statin anti-cholesterol medication, education level, physical activity and diet. There has been recent interest in the cancer-protective activity of metformin, a medication frequently used in the treatment of diabetes. 32 However, we did not find an association between metformin and prostate cancer risk (Tables 2 and 3) .
Type 2 diabetes mellitus is characterized by an initial phase of insulin resistance compensated by high serum insulin levels, followed by a later phase typified by pancreatic beta cell loss and hyperglycemia. The association between diabetes and increased incidence and mortality has been established for various malignancies. 7, 8 While several potential mechanisms, including direct effects of insulin, activation of the insulin-like growth factor pathway and altered regulation of sex hormones, 33, 34 have been linked to the adverse association between diabetes and cancer, mechanisms responsible for the protective effect of diabetes are unknown. Better understanding of the mechanisms that confer resistance to the adverse activities of insulin and insulin-like growth factor-1 may foster the development of novel preventive and therapeutic strategies, and may have important implications regarding a wide array of malignant diseases.
In conclusion, we report that over the course of over 13 years a baseline diagnosis of type 2 diabetes mellitus, but not MS, is associated with a decreased likelihood of developing prostate cancer in a cohort of men with cardiovascular disease. Owing to the observational nature of the study, causality cannot be proven.
